Theriva Biologics (NYSEAMERICAN:TOVX) Trading Down 3.7%

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX)’s share price traded down 3.7% during mid-day trading on Monday . The stock traded as low as $0.43 and last traded at $0.43. 29,671 shares were traded during mid-day trading, a decline of 68% from the average session volume of 93,100 shares. The stock had previously closed at $0.45.

Theriva Biologics Stock Performance

The firm has a market capitalization of $7.55 million, a PE ratio of -0.38 and a beta of 1.45.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC purchased a new position in Theriva Biologics during the 4th quarter valued at about $25,000. Geode Capital Management LLC purchased a new position in shares of Theriva Biologics in the 1st quarter worth approximately $81,000. Finally, BlackRock Inc. purchased a new position in shares of Theriva Biologics in the 1st quarter worth approximately $133,000. Hedge funds and other institutional investors own 6.17% of the company’s stock.

Theriva Biologics Company Profile

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases.